Phase 3 Readout~month
Phase 3 Topline: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Predniso
- Company
- ELI LILLY & Co (LLY)
- Drug
- abiraterone
- Indication
- Prostate Cancer
Other upcoming events for LLY
Phase 3 ReadoutPhase 3 Topline: Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharm
Phase 3 ReadoutPhase 3 Topline: A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placeb
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluatin
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compare
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Retat
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.